Inovio reports second quarter 2020 financial results; provides dna medicines clinical program mid-year update

Plymouth meeting, pa., aug. 10, 2020 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on rapidly bringing to market precisely designed dna medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended.
INO Ratings Summary
INO Quant Ranking